Diagnostic role of calprotectin determination in children with cystic fibrosis
Authors:   Research Centre for Medical Genetics, Moscow, Russian Federation, Maksimycheva T.Yu. ,   Research Clinical Institute of Childhood of the Moscow Region, Moscow, Russian Federation, Kondratyeva E.I. ,   Research Centre for Medical Genetics, Moscow, Russian Federation,   Research Clinical Institute of Childhood of the Moscow Region, Moscow, Russian Federation, Sherman V.D. ,   Research Centre for Medical Genetics, Moscow, Russian Federation,   Research Clinical Institute of Childhood of the Moscow Region, Moscow, Russian Federation, Voronkova A.Yu. ,   Research Centre for Medical Genetics, Moscow, Russian Federation,   Research Clinical Institute of Childhood of the Moscow Region, Moscow, Russian Federation, Zhekaite E.K. ,   Research Centre for Medical Genetics, Moscow, Russian Federation,   Research Clinical Institute of Childhood of the Moscow Region, Moscow, Russian Federation, Melyanovskaya Yu.L. ,   Research Centre for Medical Genetics, Moscow, Russian Federation,   Research Clinical Institute of Childhood of the Moscow Region, Moscow, Russian Federation, Zodbinova A.E. ,   Research Centre for Medical Genetics, Moscow, Russian Federation, Yablokova E.A. ,   I.M.Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russian Federation, Odinaeva N.D. ,   Research Clinical Institute of Childhood of the Moscow Region, Moscow, Russian Federation, Kulevatova A.Yu. ,   Research Clinical Institute of Childhood of the Moscow Region, Moscow, Russian Federation, Starinova M.A. ,   Research Centre for Medical Genetics, Moscow, Russian Federation
Published: November 2022

Cystic fibrosis (CF) is characterized by chronic intestinal inflammation and small intestinal bacterial overgrowth. In recent years, the correlation between calprotectin and gastrointestinal manifestations (intestinal diseases, abdominal pain syndrome) in CF has been actively studied. Objective. To study the level of fecal calprotectin in children with CF and evaluate its clinical significance. Patients and methods. A total of 67 children with CF aged between 1 and 18 years (mean age 7 (±4.0) years) were examined using a cross-sectional study design. All children were divided into 3 groups according to calprotectin concentrations: group 1 – <50 μg/g, group 2 – 50–120 μg/g, group 3 – >120 μg/g. Clinical and anamnestic data, nutritional status, and microbiological diagnosis were analyzed; a microbiological analysis of the large intestinal microbiota was conducted to determine the nature of biocenosis disorders; a coprological analysis was performed; fecal calprotectin concentrations were evaluated. Conclusion. Calprotectin cannot serve as a marker of enterocolitis/enteropathy in CF, which is сconsistent with the findings of the ESPGHAN expert group. Calprotectin determination in children with CF without clinical manifestations of inflammatory bowel disease is not informative. Calprotectin does not refer to indicators that determine the presence of infectious enterocolitis, the severity of the course and the outcome of the disease. Key words: calprotectin, children, cystic fibrosis, microbiota, intestinal syndrome, clostridia